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Osteosarcoma, a highly malignant disease, is the most common primary bone tumor and is frequently found in children and
adolescents. In order to isolate antibodies against osteosarcoma antigens, a combinatorial osteosarcoma Fab library displayed on
the surface of phages was used. After three rounds of selection on the surface of tumor cells, several osteosarcoma-reactive Fabs
were detected. From these Fabs, ﬁve were better characterized, and despite having diﬀerences in their VH (heavy chain variable
domain)andVκ(kappachainvariabledomain)regions,theyallboundtoaproteinwiththesamemolecularmass.Furtheranalysis
by cell ELISA and immunocytochemistry suggested that the Fabs recognize a membrane-associated tumor antigen expressed in
higher amounts in neoplasic cells than in normal tissue. These results suggest that the human Fabs selected in this work are a
valuable tool for the study of this neoplasia.
Copyright © 2009 Carmela Dantas-Barbosa et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Osteosarcomaisthemostcommonprimarybonetumorthat
aﬀects children and young adults [1]. It is highly malignant,
characterized by a high propensity to metastasize [2]. Use
of multiagent chemotherapy pre- and postoperatively has
signiﬁcantly improved the outcome in the last 30 years,
leading to a 5-year disease-free survival for patients with
localized tumors in the 20% to 60% range [3]. Despite
the use of these drugs, approximately 30% of patients with
localizeddiseaseand60%ofpatientswithpulmonarymetas-
tases succumb to the illness [4]. Osteosarcoma is a complex
neoplasia. Cytogenetic analysis has revealed multiple chro-
mosomal rearrangements without a typical translocation,
as can be seen in Ewing’s sarcoma. In recent years, the
immunocytochemical subclassiﬁcation of osteosarcomas has
signiﬁcantlyenhancedtheaccuracyofpathologicaldiagnoses
[5], suggesting that new immunochemical markers could
further improve diagnosis and prognosis. Recently, Salas et
al. [6] introduced Ezrin expression as a prognostic factor for
the survival rate of patients with conventional osteosarcoma,
correlating its expression with tumor progression. It was
also shown that Ezrin is useful as an immunohistochemical
marker to diﬀerentiate between chondroblastic osteosarco-
mas and conventional chondrosarcomas [7]. However, other
osteosarcoma markers are required to further characterize
this complex, multifactorial neoplasia.
Antibodies to tumor mark are being used to treat diﬀer-
ent forms of cancers. Among the currently FDA approved
antibodies, some of them are now under clinical trials to
osteosarcoma (http://www.clinicaltrials.org/). The success of
the treatment is somewhat related to the antibody origin; in2 Journal of Biomedicine and Biotechnology
general it is expected that humanized or fully human anti-
bodies are better tolerated than murine monoclonal ones. To
isolate such potential biopharmaceuticals, many approaches
can be used, including the phage display technique. The
use of the phage display technique can lead to the isolation
of either antibodies or peptides able to discriminate tumor
cells [8]. In a traditional approach, the identiﬁcation of the
tumor marker is the ﬁrst step, after that it is necessary to
isolate an antibody against this marker. Using a Fab phage
display library, these steps can be merged into one, and it
is possible to identify antigens without previous knowledge.
T h eu s eo fc o m p l e xa n t i g e n ss u c ha sc e l lm e m b r a n e s
broadens the possibility of ﬁnding diﬀerentially expressed
markers. However, as a more complex antigen source is used,
the techniques employed to separate bound phages from
unbound phages become more diﬃcult. This usually makes
selection on cell surfaces much more complex than selection
using puriﬁed antigens. Focusing on this challenge, diﬀerent
selection procedures have been developed. Among these
procedures, a method called BRASIL (Biopanning and Rapid
Analysis of Selective Interacting Ligands) was speciﬁcally
designed to isolate phages able to bind to the cell surface [9].
In order to isolate anti-osteosarcoma fully human Fabs,
we used a previously constructed combinatorial Fab phage
display library produced with antibody repertoires from
osteosarcomapatients,relyingonthefactthattheseantibody
repertoires could be enriched with antibodies against the
patients’ own tumors [10]. Here, we report the utilization
of this library for panning Fabs against the surface of
osteosarcoma cells. The selection procedure was adapted
from that of the BRASIL method for using a phage antibody
library [9]. This is the ﬁrst report of the use of the BRASIL
method with a human Fab library. After three rounds of
selection against the cell surface of an osteosarcoma cell
line, we were able to identify many reactive Fabs, most of
them sharing similar V genes. Five Fabs were chosen for
further analysis, including western blot, cell ELISA, and
immunocytochemistry. Our data revealed that these Fabs
recognize a membrane antigen that is more widely expressed
in the osteosarcoma cells compared to normal osteoblast and
ﬁbroblast cells. These results suggest that these human Fabs
couldbefurtherusedtoimprovethediagnosisandprognosis
of osteosarcoma.
2.MaterialsandMethods
2.1. Cell Lines. The human osteosarcoma cell lines U2
OS (HTB-96) and Saos-2 (HTB-85), and the fetal normal
osteoblast cell line hFOB1.19 (CRL-1172) were purchased
from ATCC and cultured as recommended. A short-term
culture of normal human ﬁbroblasts was cultured at 37
◦C
in 5% CO2 with Ham’s F10 medium supplemented with
100U/mL of penicillin, 100μg/mL of streptomycin, and 10%
FBS.
2.2. Panning of the Fab Phage Library with Osteosarcoma
Cells. A combinatorial Fab phage display library generated
fromtheantibodyVregionsofelevenosteosarcomapatients,
containing 2.7 × 108 diﬀerent forms, was constructed previ-
ously [10] and used for selection according to the BRASIL
method [9]. Brieﬂy, the cultured cells were collected with
PBS and 5mM EDTA and then washed with the medium
deﬁned for each lineage, resuspended in culture medium
containing 1% BSA at a cell density of approximately 1×106
cells per mL, and incubated with 1 × 1011 plaque forming
units (pfu) of phage for approximately 1.5 hours on ice with
sporadic gentle mixing. After that, the cell-phage suspension
was transferred to the top of a nonmiscible organic lower
phase(a9 : 1mixtureofdibutylphthalate:cyclohexane)and
centrifuged at 1000g for 10 minutes at room temperature.
The tube was snap frozen in liquid nitrogen, and the cell-
phage pellet was used to infect a log-phase culture of
Escherichia coli (strain XL1-Blue). In the selection procedure
using the surface of U2-OS cells, we also performed a
preclearing step before the third selection cycle. To do
this, the phages were incubated with normal hFOB 1.19
osteoblasts, and, after separation by centrifugation through
the organic phase, the supernatant containing the unbound
phages (in the aqueous upper phase) was incubated with
U2-OS osteosarcoma cells as described above. The selected
phages were ampliﬁed by E. coli infection according to the
procedure described elsewhere [11] and were then used in
the next selection cycle.
2.3. Expression of Soluble Fab Fragments. DNA was extracted
from the bacterial pellet obtained after each round of
selection using a QIAprep spin miniprep Kit (Qiagen),
and then used to transform HB2151 E. coli cells for
production of soluble Fab without the ﬁlamentous phage
Gene III fusion protein partner. Individual carbenicillin-
resistant HB2151 colonies were picked and grown overnight
(ON) at 37
◦C in a 96 deep well plate in 1mL SB medium
containingcarbenicillin(100μg/mL)andglucose(1%).After
this incubation, the cultures were used to produce two
replica plates: one for a glycerol stock and the second for
the production of the soluble Fabs themselves. The original
ON culture plate was centrifuged, and plasmid DNA was
extracted from the E. coli using the QIAprep Kit. Fab
production was performed by inoculation of 1.5mL of SB
medium containing carbenicillin (100μg/mL) and glucose
(1%) with 50μL of the ON culture. Cultures were incubated
at 37
◦C, shaking at 250rpm, until they reached an OD of
0.9 at 600nm. The cultures were then centrifuged, and fresh
SB medium containing carbenicillin (100μg/mL) and IPTG
(2mM) was added, followed by incubation at 30
◦Cf o ra n
additional 18 hours. Supernatants containing the soluble
Fabs were used in the dot blot and ELISA assays.
For large-scale Fab production, the procedure was the
same as described above, except that phages were produced
in 100mL of SB medium E. coli culture. Supernatants were
concentrated using Centriprep 10 ﬁlter units (Millipore) and
buﬀer exchanged in PBS. Puriﬁcation of Fabs was performed
using Ni-NTA resin (Qiagen) under nondenaturing condi-
tions according to the manufacturer’s instructions. Proteins
were analyzed by SDS-PAGE [12].
2.4. Sequence Analysis. Sequencing reactions were prepared
with reverse primers speciﬁc for the VH and VL regionsJournal of Biomedicine and Biotechnology 3
(CH: 5 CGCCTGAGTTCCACGACACC3 ,M M B 4 :5  GCT-
TCCGGCTCGTATGTTGTGT3 ,C κ:5  AGAGGAGTC-
CAGATTTCA3 ,a n dM M B 5 :5  CGTTTGCCATCTTTT-
CATAATC3 )[10]andwereperformedusingETTerminator
(GE-Healthcare) in a MegaBace 500 plus sequencer (Molec-
ularDynamics). Alignments weredone using IgG Blastatthe
NCBI blast server (http://www.ncbi.nlm.nih.gov/blast)a n d
with the program BioEdit [13]. The Kabat numbering and
CDR deﬁnitions were adopted from Andrew Martin’s web
site (http://www.bioinf.org.uk/abs/).
2.5. Analysis of Binding of Selected Fabs to Total Protein
Extracts and to the Cell Surface by ELISA. Ninety-six well
plates were coated with 100μLo fa1 0μg/mL total protein
solution prepared from osteosarcoma and osteoblast cells
as described in the next section. Human serum albumin
was used as a mock protein. The coating was carried out
overnight at 4◦C. The plates were then blocked with 3%
BSA and incubated with 100μL of the induced supernatant
from each selected clone. The supernatant from the empty
parental plasmid (pComb3X) E. coli culture was assayed
as a negative control. Fab binding was detected with a rat
anti-HA (hemagglutinin decapeptide tag) HRP-conjugated
antibody from Roche, followed by the ABTS peroxidase
substrate. For selecting individual clones, a threshold value
was arbitrarily set at ten times greater than the value
obtained for the empty vector and at least three times greater
than the value obtained for the incubation with proteins
from normal osteoblast cells.
Cell ELISA was performed according to the protocol
adapted from Williams and Sharon (2002) [14]. Brieﬂy,
polystyrene 96-well tissue culture plates were seeded with
2 × 106 U2-OS, Saos-2, or ﬁbroblast cells in 200μLo f
culture medium deﬁned for each cell lineage supplemented
with 10% (v/v) FBS and incubated for 30 hours. The cells
were ﬁxed with 4% formaldehyde in PBS for 20 minutes at
room temperature followed by two washes with PBS. The
washed cells were incubated with 100μL of the induced
supernatant from each clone or with the puriﬁed Fab. The
empty parental pComb3X plasmid supernatant was used as
a negative control. Detection of Fab binding was performed
as described above.
2.6. Immunodetection of Osteosarcoma Fab Ligands. Protein
extracts from U2-OS and ﬁbroblast cells were prepared in
cold lysis buﬀer (0.5% NP-40, 0.3% Triton X 100, 50mM
Tris HCl pH 8.0, 5 mM MgCl2, 0.5mM EDTA, 1mM ATP,
1mM DTT, 10% glycerol) and complete mini-EDTA-free
protease inhibitor cocktail tablets from Roche. Total protein
extracts were separated by SDS-PAGE under reducing con-
ditions and transferred to nitrocellulose membranes (GE-
Healthcare). After blocking with 5% skim milk—TBST at
room temperature for 1 hour, the membranes were probed
with one of the ﬁve puriﬁed Fabs (0.02μg / m L )f o r2h o u r s
at RT and washed 3 times with TBST (50mM Tris-HCl,
pH 7.5, 150mM NaCl, 0.05% tween 20). The membranes
were then incubated with a rabbit anti-HA (hemagglutinin
decapeptide tag) antibody (Santa Cruz) diluted 1 : 1000 for 1
hour, washed again and incubated with anti-rabbit HRP at a
1 : 5000 dilution. Bands were visualized using an ECL Super-
Signal West Pico Chemiluminescent Substrate detection kit
(Thermoscientiﬁc). To control loading diﬀerences, a rabbit
anti-alpha-tubulin antibody (AbCAM) was used instead of
the selected Fabs.
2.7. Immunocytochemistry. Cultures of U2-OS and human
ﬁbroblast cells grew until they reached 70–90% conﬂuency
on a slide chamber. The cells were then washed twice with
PBS and ﬁxed and permeabilized by immersion in precooled
methanol for 6 minutes at −20
◦C. After two washes with
PBS, the slides were incubated with 2% BSA (w/v) and 5%
normal goat serum (v/v) for 30 minutes. After an overnight
incubation at 4◦Cwi t h1 5μL of puriﬁed Fabs, the slides were
washed and incubated with 1 : 200 anti-HA antibody (Santa
Cruz) for 45 minutes, followed by an incubation with a goat
anti-rabbit IgG-FITC at 1 : 2000 (Sigma) in a moist chamber
inthedark.AfteradditionofDAPII,theslideswereobserved
with an Axiolab ﬂuorescence microscope (Zeiss) using the
Applied Imaging Cytovision software.
2.8. Immunohistochemistry. Archived, formalin-ﬁxed, para-
ﬃn-embedded tissue sections (4μm) were deparaﬃnized in
xylene and rehydrated using a series of alcohol and distilled
water solutions. Endogenous peroxidases were quenched by
incubation with 10V H2O2 for 10 minutes, followed by
microwave antigen retrieval in 10mM sodium citrate buﬀer,
pH 6.0. Puriﬁed anti-osteosarcoma Fabs at 200μg/mL,
diluted to 1 : 200 (N-H7) and 1 : 20000 (O-G11),
were incubated with tissue sections for 1 hour at room
temperature. After rinsing with phosphate-buﬀered saline,
the slides were incubated for 30 minutes with rabbit anti-
HA antibody (Santa Cruz), diluted 1 : 200 in 1% BSA-
PBS, and then incubated with a biotinylated goat anti-
rabbit IgG (Rockland). After the antibody incubations, the
slides were washed with Tris-based buﬀer and then incu-
bated with streptavidin-conjugated horseradish peroxidase
(LSAB+ kit
TM, Dako) and DAB as the chromogen. The
sections were counterstained with Harry’s hematoxylin and
covered with Entellan (Merck).
3. Results
3.1. Selection of Fabs that Bind to Osteosarcoma Cells. To
selectrecombinantantibodyfragmentsthatbindtoosteosar-
coma cells, we used a human Fab phage display library
constructed from PBMCs of eleven osteosarcoma patients
[10] using two diﬀerent cell lines: Saos-2 osteosarcoma
cells (N Fab clones) and U2-OS osteosarcoma cells (O Fab
clones). Both panning approaches were repeated three times.
For the U2-OS cells, we included a negative selection cycle
before the third round, in which the phages were ﬁrst
adsorbed to normal hFOB 1.19 osteoblast cells, followed
by panning against osteosarcoma cells. One hundred eighty
three clones from the second and third rounds of selection
from both approaches were screened by dot immunoblot
using an anti-HA antibody to identify Fab expressing clones.4 Journal of Biomedicine and Biotechnology
Table 1: Reactivity of randomly selected Fabs toward tumor antigens in ELISA assays.
Cycle of selection(System) Clones assayed Positive clones in Cell ELISA
a Positive clones on Total Protein Extractsb
2nd (N) 40 10 28
3rd (N) 39 NT
c 13
2nd (O) 48 0 1
3rd (O) 40 1 4
aA clone was considered positive if the absorbance at 405nm was three times greater than the absorbance found for hFOB 1.19 cell surface binding.
bA clone was considered positive if the absorbance at 405nm was ten times greater than the absorbance observed for empty vector supernatant.
cNT = Not tested.
We found that 67% of the N clones and 46% of the O clones
gave positive signals, demonstrating that these clones express
reactive Fabs (data not shown). Individual Fab-expressing
clones were tested for the ability to bind to osteosarcoma
cell proteins by ELISA using two diﬀerent strategies. The ﬁrst
approach evaluated Fab binding to ﬁxed osteosarcoma cell
monolayers, and the second approach evaluated Fab binding
to total protein extracts from osteosarcoma cells. Seventy-
nine clones from the N system and eighty-eight from the O
system were tested. Table 1 summarizes these results. Clones
showing an A450 of less than 0.1 (similar to supernatants
without Fab) were considered nonbinders.
The most reactive clones were tested further in another
ELISA assay using protein extract from osteosarcoma cells
and normal osteoblast cells. An unrelated protein was
included as a negative control. Triplicates of 27 clones were
tested in this second trial, including 16 from the second and
6 from the third rounds of the N system and 2 clones from
the second and 3 from the third round of the O system. The
results of this assay conﬁrmed the reactivity of the Fabs with
osteosarcoma cells (Figure 1).
3.2. VH and VL Repertoire Usage of Selected Fabs. The
VH and VL coding regions of the 20 most reactive clones
were determined by sequencing (Figure 2). Analysis of the
deduced amino acid sequences of the corresponding V genes
indicated that all VH and Vκ chains were distinct from the
sequences (51VH and 74Vκ) previously described from the
original library of randomly chosen clones [10]. The VH
sequencesrevealedthatallclonesbelongedtotheVH3family
and that their CDR3 varied in length from 6 to 14 amino
acid residues. The majority of the clones (12/20) had a VH3-
7 gene segment and a CDR3H of eight amino acids in length.
An unusual histidine residue was predicted at position 52a of
clone O-G11. This was ﬁrst reported in the original library.
The presence of the amino acid cysteine (C) at position 79 in
framework 3 is a striking characteristic, and it was found in
12 clones harboring the VH3-7 gene segment, as can be seen
in the N-H7 clone.
The amino acid sequences encoded by the Vκ genes also
diﬀered from those reported for the unselected repertoire.
TheO2VκfamilyclonesN-E8andO-C10hadaconservative
valine substitution at position 48 (I48V), and clones O-
F4 and O-G11 (B3 Vκ family) had a nonconservative
phenylalanine substitution at this same position (I48F). This
rare mutation is reported to occur in less than 1% of the Vκ
sequences [15], and was present in diﬀerent clones of the
original library [10]. The B3 family clones also presented a
previously observed conservative change at the key position
64 (G64A). The predominance of clones harboring the
VH3.7 (12/20) and A17 (11/20) gene segments supports the
speciﬁc ligand selection.
Based on the results of the ELISA and the DNA sequen-
cing, we chose ﬁve diﬀerent Fabs for further analysis empha-
sizing their reactivity. The clones chosen were: N-H7 (VH3-
7—A17, frequency 11/20), N-E8 (VH3-23—O2, frequency
1/20), N-H10 (VH3-20—A30, frequency 1/20), O-F4 (VH3-
23—B3, frequency 1/20) and OG-11 (VH3-74—B3, fre-
quency 2/20). The Fabs were produced in 100mL cultures
and puriﬁed using metal aﬃnity columns before use in
further analyses.
3.3. Clones N-H7, N-E8, N-H10, O-F4, and O-G11 Recognize
the Same Overexpressed Osteosarcoma Protein. Immunoblot
experiments were carried out for an initial characterization
of the molecules in whole cell lysates derived from the
osteosarcoma cell line U2-OS or from normal ﬁbroblasts
that were detected by the chosen Fabs. From this analysis,
an intense 80kDa band and a weaker 50kDa band were
observed for all analyzed Fabs, suggesting that all clones
recognized the same proteins and that these proteins are
present in both osteosarcoma cell lines (Saos-2 and U2-
OS). The same pattern was observed at a lower intensity
when normal ﬁbroblasts were probed, suggesting that these
proteinsareoverexpressedinmalignantbonecells(Figure 3).
3.4. Pattern of Fab Staining of Osteosarcoma Cells and
Tissue. Further analysis of Fab reactivity was addressed by
comparing the ability of the antibody fragments to bind to
monolayers of osteosarcoma cells and normal ﬁbroblasts by
cell surface ELISA. Figure 4 shows the conﬁrmation that the
puriﬁed Fabs recognized a protein present in both kinds of
cells (tumor and normal human ﬁbroblast). However, the
signal obtained was at least twice as strong for the tumor
cells as for the normal ﬁbroblasts, suggesting overexpression
of the antigen in the osteosarcoma cells. The clones obtained
from selection in Saos-2 cells (the N system) were tested
againstSaos-2andU2-OSosteosarcomacelllines.Theclones
from the O system were assessed using only U2-OS cells in
addition to the normal human ﬁbroblasts.
The antigen-binding speciﬁcity of each selected Fab was
also evaluated by measuring the cell surface binding capacity
using an immunoﬂuorescence assay. Considering that the
ﬁve Fabs apparently recognized the same protein, furtherJournal of Biomedicine and Biotechnology 5
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Figure 1: Selection of Fab clones able to recognize osteosarcoma cell protein extracts. Protein extracts from Saos-2 cells (horizontal line
bars, panel (a)), U2-OS cells (horizontal lines, panel (b)), and h FOB 1.19 (normal human osteoblast, black bars, both panels) were used
to coat a 96-well plate. E. coli supernatants from the N system (panel (a)) or the O system (panel (b)) Fab clones were added to the plate.
After washing, the bound Fabs were detected using rabbit anti-HA antibody followed by an HRP-conjugated anti-rabbit antibody. The
experiments were performed in triplicate. The Fabs were also added to HSA- (human serum albumin) coated wells (diagonal line bars, both
panels) as a negative control. Supernatant from an empty vector E. coli culture was also used as negative control (pComb). The absorbances
were measured at 405nm.
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Figure 4: Cell surface ELISA. The selected puriﬁed Fabs were
added to monolayers of Saos-2 cells (light gray bars), U2-OS cells
(dark gray bars), and human ﬁbroblasts (black bars). The bound
Fabs were detected using rabbit anti-HA and HRP-conjugated anti-
rabbit antibodies. Human serum albumin (white bars) was used as
negative control. The absorbances were measured at 405nm.
investigations were done mainly with the N-H7 (Figure 5,
panels (a) and (b)) and O-G11 (Figure 5, panel (c), (d), (e)
and(f))Fabs.TheseFabswerechosenbasedonthefrequency
of N-H7, whose VH and VL sequences were shared with 10
otherselectedclones,andonsingularityofO-G11,asitcame
from the third round of the O system, after depletion on
normal osteoblast cells. The immunoﬂuorescence staining
pattern suggested that these two Fabs interact with a cell
membrane component. The staining was dot like for the
osteosarcoma cell line U2-OS (Figure 5, panels (b) and (d)),
but only a vague staining was observed for the normal
ﬁbroblasts (Figure 5, panels (a) and (c)).
Immunohistochemistry analyses performed using
archived normal bone and osteosarcoma sections conﬁrmed
the membrane staining pattern. Panels (e) and (f) of
Figure 5 show the reactivity of the O-G11 Fab in a normal
bone section and in an osteosarcoma section, respectively.
There was visible staining in the bone marrow adipocytes
and in the osteoblasts in the normal tissue (Figure 5,
(a) (b)
(c) (d)
(e) (f)
Figure 5: Indirect immunoﬂuorescence staining and immunohis-
tochemistry were performed with the selected Fabs. Methanol-ﬁxed
ﬁbroblasts ((a) and (c)) or U2-OS osteosarcoma cells ((b) and (d))
were stained with Fab N-H7 ((a) and (b)) or Fab O-G11 ((c) and
(d)). Fab O-G11 was also used to stain to normal bone (e) (200x)
and osteosarcoma tissue (f) (400x) sections. The osteoblasts in
normal bone are arranged in lines; the empty region corresponds
to bone trabecules dislocated during washing. These results are
representative from four diﬀerent osteosarcoma cases analyzed.
panel (e)), but staining was less intense than the staining
observed in osteosarcoma tissues (Figure 5, panel (f)).
This demonstrated the preference of O-G11 for tumor cell
membranes.
4. Discussion
This work has focused on the isolation of antibodies
against osteosarcoma cells using a human Fab phage display
library that was constructed from antibody repertoires
of osteosarcoma patients. The selection was accomplished
using whole cells as the antigen source, with the goal of
isolating novel antiosteosarcoma antibodies. This strategy
posesanadvantageoverthetraditionalstrategyusingprotein
extracts, as the library probes the cell surface allowing
the identiﬁcation of protein and nonprotein antigens [16].
Despite some intrinsic diﬃculties, such as the binding to a
rareantigenandthelossofnonbinderphagesassociatedwith
this approach [17], successful examples have been reported.Journal of Biomedicine and Biotechnology 7
Among the successful approaches using whole cells is
the BRASIL method, described as a very eﬃcient way to
rescue ligand phages [9]. Until now, this technique has been
used only with peptide libraries [18, 19]. We successfully
adapted the BRASIL protocol for use with a Fab library.
We performed three rounds of selection, and the reactivity
analysis of the second and third rounds revealed that after
two rounds we were able to identify Fabs that bind to
osteosarcoma cells. The ability to select speciﬁc tumor
binders is usually attributed to the depletion step [20], but
the omission of this step does not impair the isolation
of speciﬁc binders [21, 22]. Our data suggest that the
introduction of a negative selection step (only before the
third selection cycle for the O system) did not signiﬁcantly
improvetheisolationofspeciﬁcFabs,sincetheNandOFabs
apparently recognized the same antigen (Figure 3). The lack
of more eﬀective selection in the O system could also be a
consequence of the small number of positive clones in round
2, just prior to the depletion step (Table 1).
Selected Fab clones were chosen based on their Fab
coding sequences (Figure 2) and on their reactivity to tumor
antigens assayed as a monolayer of osteosarcoma cells
(Table 1) and total protein extracted from cells (Table 1,a n d
Figure 1). These assays were carried out to favor the binding
of antibodies that recognize the physiological conforma-
tions of the antigen(s). The ﬁve clones that were further
characterized all recognized the same antigen (Figure 3),
despite the fact that some of them reacted diﬀerently in the
cell ELISA or protein ELISA assays, suggesting that these
Fabs may recognize diﬀerent epitopes [23]. Comparing the
ELISA results (Figures 1 and 4), we observed that the results
were similar if we used ﬁbroblasts or normal osteoblasts, as
negative controls.
Another important ﬁnding was that the same clones
were recovered after selection. Also, it is remarkable that
the majority of these clones (11 out of 20) harbored the
same sequence (A17, for Vκ and VH3.7 for the heavy chain,
Figure 2). This cannot be attributed to a bias in the Fab
library, since all of the sequenced clones from rounds two
or three had diﬀerent VH and Vκ sequences compared to
the original library [10]. The emergence of clones with a
restricted diversity of V gene fragments is a feature that
accounts for the selection of speciﬁc ligands, as was reported
when other antibody phage display libraries were used
to isolate high aﬃnity immunoglobulins [22, 24]. Clones
sharing VH3-7 and A17 were the majority of the clones
identiﬁed in our selection process. There was one exception
among the 20 sequenced clones: clone N-B1, which has the
VH3-7 gene associated with an A30 Vκ gene. The eﬀect of
this rare association on aﬃnity and selectivity can be further
addressed.
Apparently, all of the ﬁve chosen clones, each repre-
senting a distinct gene family, recognized the same protein
proﬁle. This was also true for Fabs selected against diﬀerent
osteosarcoma cell lines, Saos2 and U2-OS (clones from the
N and O systems, resp.). Similar results have been reported
by Aryee and coworkers regarding six diﬀerent scFvs selected
against FLI1[ 25]. Our data point to the existence of an
immunodominant antigen. The immunodominance phe-
nomenon has been frequently observed in phage display
analysis. In two separate studies with melanoma, one using
a scFv phage display library constructed from blood from
melanoma patients and the other using an Fab library, the
authors were able to isolate only one positive scFv and
Fab, respectively [26, 27]. This is in agreement with our
results using two diﬀerent cell lines, Saos-2 and U2-OS, as
the antigen source. This does not exclude the possibility
of binding to diﬀerent epitopes on the same protein, and
further epitope mapping must be carried out. Another
interesting characteristic was the ability of the selected
antibodytobindtotheantigeninbothnativeanddenaturing
conditions (Figures 1(a), 1(b) and 3), suggesting a linear
rather than a conformational epitope.
The immunoﬂuorescence staining pattern (Figure 5)
was typical for Fabs recognizing a membrane-associated
ligand, as expected for a cell surface selection procedure.
The background in immunohistochemestry was high, and
although it was possible to see staining of normal cells, the
staining was stronger with the osteosarcoma tissues. The O-
G11 Fab gave a very strong background even when used
as much as 1 : 20000 dilution (estimated concentration
of 0.1ng/mL). Usually the concentration of commercial
antibodies is about 200μg/mL, and they are used at dilutions
of 1 : 50–1 : 200 in immunohistochemistry assays. O-G11
recognized the osteoblasts in a very strong way and also
reactedwithadipocytesinthebonemedullabutdidnotstain
the blood vessel (data not shown).
It is diﬃcult to measure the strength of the sig-
nal in osteosarcoma cells and compare it to the signal
strength from normal controls in cell imaging approaches,
such as immunoﬂuorescence and immunohistochemistry.
This became more evident when a quantitative assay was
employed (Figure 3). The higher level of the antigen in
the osteosarcoma cells was conﬁrmed by cell surface ELISA
(Figure 4).Intheseassaysourresultsshowedthattheantigen
recognized by these Fabs was expressed at a level two times
higher in the osteosarcoma cells than in normal tissue. This
antigen is a potential marker for osteosarcoma, and investi-
gation into the identity of this antigen should be completed.
Inconclusion,thisworkdescribestheisolationofﬁvedif-
ferent human Fabs that recognize osteosarcoma-associated
antigens. These monoclonal antibody fragments harbored
diﬀerent VH and VL domains but apparently recognized
the same protein. Our data suggest that this protein epitope
is found in lower amounts in normal cell lines than in
osteosarcoma cell lines and is an immunodominant antigen.
As these are fully human antibodies, they can be further
characterized, aiming their use as biopharmaceuticals.
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